A la une >> Communiqués presse membre

Tags: augmentation de capital, Delansorne, étude clinique, hybrygenics, levée de fonds, loi, maladies prolifératives, OSEO, phase 2, phase II, psoriasis, tepa

This entry was posted on Friday, September 30th, 2011 at %I:%M %p and is filed under A la une, Communiqués presse membre. You can follow any responses to this entry through the RSS 2.0 feed. Responses are currently closed, but you can trackback from your own site.